NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading RGNX? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Stabilize and grow revenue after expected decline: revenue decline -1% vs <10%.
View ThesisRevenue is contracting — down about 44% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, the balance sheet.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 65% in its worst 12-month stretch.
View RiskRGNX's growth depends on maintaining cash to fund operations into early 2027. Recent financial performance is weak and below its industry peers. Revenue growth expectations look full, as the market prices in more growth than forecasted. RGNX trades at 6.0× price-to-sales, below the peer median of 8.7×. If RGNX misses again next quarter, the miss probability is 59%. Peer multiples imply a price about 45% above where it trades. This read is provisional.
Trailing returns as of 2026-07-31. RGNX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 11 analysts currently covering RGNX (as of Jul 2026).
Based on 5 Wall Street analysts offering 12-month price targets for RGNX in the last 4 months.
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Threatens: Fund operations into early 2027
Concerns about cash runway affect funding operations.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $9.69
The last 12 months of price, then the range of analyst 12-month targets from today’s $9.69.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Address FDA rejection of RGX-121
Hold on RGX-121 CRL impacts regulatory objectives.
Threatens: Resolve GSK sublicense dispute
Lower price target due to regulatory uncertainty.
Advances: Address FDA rejection of RGX-121
Accelerated approval path for RGX-202 is positive.
